Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

HROWBullishM&Anews

High materiality9/10

Harrow closes TYRVAYA acquisition, expanding dry eye portfolio with nasal spray

Oct 5, 2026, 7:19 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Acquisition closes with a defined revenue ramp (>$30M in 2027) and near-term capacity from 40 new reps; expected uplift to top-line and cross-selling potential with VEVYE increases near- to medium-term upside, despite ongoing integration risk.

AI summary

What happened, with direct paths to the underlying reporting

Harrow completed the TYRVAYA acquisition from Viatris, adding a second differentiated dry-eye therapy to its Ocular Surface platform. The deal brings ~40 Viatris personnel in Q4 2026, a single commercial organization, and TYRVAYA is forecast to generate more than $30 million in 2027 revenue. The integration supports cross-brand engagement with VEVYE and expands access to eyecare professionals.

Harrow closes TYRVAYA acquisition; cash $30M with up to $70M milestones.
TYRVAYA is FDA-approved nasal spray; expands Harrow’s dry eye portfolio.
40 Viatris personnel to join Harrow’s Ocular Surface team in Q4 2026.
TYRVAYA revenue ramp expected; >$30M in 2027.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.